Background. Tumoral calcinosis is an autosomal recessive disorder characterized by ectopic calcification and hyperphosphatemia. Methods. We describe a family with tumoral calcinosis requiring amputations. The predominant metabolic anomaly identified in three affected family members was hyperphosphatemia. Biochemical and phenotypic analysis of 13 kindred members, together with exome analysis of 6 members, was performed.
relative roles of hyperparathyroidism, hyperphosphatemia, vitamin D therapy, calcium homeostasis and the uremic milieu contributing to vascular calcification are not completely understood. Since vascular injury contributes to significant morbidity and mortality in these settings, its pathogenesis is an active area of clinical and experimental research [1, 2] .
Fibroblast growth factor 23 (FGF23) is produced in osteoblasts/osteocytes and has a central role in regulating calciumphosphate metabolism [3] . FGF23 decreases proximal tubule expression of the sodium-phosphate cotransporters NPT2a and NPT2c, inducing phosphaturia. 1,25(OH) 2 vitamin D stimulates FGF23 synthesis, likely through binding to the FGF23 promoter. Additionally, in a negative feedback loop, FGF23 decreases 1α-hydroxylase activity impairing calcitriol synthesis and increases 24-hydroxylase activity causing calcitriol degradation, secondarily reducing gastrointestinal phosphate absorption. Thus, FGF23 is the most important direct effector of phosphate balance known [1, 2] . We report a family with tumoral calcinosis (TC) with an atypical phenotype of severe vascular calcification requiring amputation. An FGF23 mutation inherited in compound heterozygosity with a null allele was identified along with marked hyperphosphatemia. In the absence of other vascular calcification risk factors, hyperphosphatemia was the predominant metabolic abnormality identified to explain the severe vascular calcification.
M AT E R I A L S A N D M E T H O D S

Subjects
The study was reviewed and approved by the Los Angeles Biomedical Research Institute Institutional Review Board. After obtaining informed consent, blood samples from family members were processed for measurements and for DNA extraction and analysis. Full exome sequencing was performed on DNA extracted from lymphocytes, with confirmation using Sanger sequencing. DNA from the selected individuals was sheared and selectively amplified using the Agilent SureSelect Human Whole Exon 50 Mb capture kit according to the manufacturer's protocol. Each enriched library was sequenced on its own lane of an Illumina GAII sequencer. The sequencing metrics were determined using the HSmetrics ultility from the Picard software package.The mean bait coverage ranged from 102× to 134× of the sequenced exome. A CLIA-certified confirmatory analysis was performed from DNA extracted from a buccal DNA preparation on the proband only. The 13 living family members ( Figure 2) were genotyped, using the Affymetrix Genome-Wide Human SNP Array 6.0 in the Genotyping and Gene Expression Core at Case Western Reserve University using standard methods. Genotype quality was assessed by calculating the random Contrast QC, which ranged from 1.03 to 3.59 with an average of 2.71, and the QC Call Rate, which ranged from 89.74 to 99.37% with an average of 97.81%.
Immunohistochemistry
Formalin-fixed sections from the proband's amputation were baked and then run on automated immunohistochemistry instruments using the following antibodies and detection systems. Primary antibodies included osteonectin (Leica, IL, USA; 1 : 100) pretreated with low pH, and tartrate-resistant acid phosphatase (TRAP; Leica, IL, USA; predilute) pretreated with high pH, both run on Leica bond III using DAB detection; and smooth muscle actin (Leica, IL, USA; prediluted) without pretreatment, CD34 (Epitomics, CA, USA; 1 : 100) pretreated with high pH and CD163 (Leica, IL, USA 1 : 100) pretreated with high pH, all run on Ventana Ultra using Ultraview Red detection. After staining, all slides were counterstained with Mayer's hematoxylin and bluing reagent.
Genotyping and loss of heterozygosity analysis
The data were loaded into Affymetrix Genotyping Console and genotypes called using the default settings. The samples were also analyzed for loss of heterozygosity (LOH) using the Genotyping Console's default settings. The regions identified in each sample were compared to determine which regions were found in affected family members but not in unaffected members. Only one region was found in the proband and affected siblings but in no other family member ( Figure 4 ). The overlapping region from the three samples was on 12p13 between 1078103 and 6323300. The affected individuals shared the same homozygous genotypes in this region while the unaffected father and brothers had a differing genotype on both the Affymetrix array and in the exome sequencing data, confirming the LOH. The size of this region indicates that the affected individuals lost this portion of their maternally inherited chromosome 12. Two of the short-listed variants are in this region, including the FGF23 variant. The mutated FGF23 inherited from the father by the proband and two affected siblings would be the only copy expressed by the affected individuals given their loss of that portion of their maternally inherited chromosome.
SNP and inDel identification
Exome sequencing of the samples was done using an enriched library created, using the Agilent SureSelect Human All Exon Kit after shearing of the DNA on a CovarisTM S2 system (Covaris, Inc., Woburn, MA, USA) following the manufacturer's protocol for 200-300 bp fragments. Samples were run on two lanes of a GA Illumina sequencer. Sequencing reads passing quality control were aligned using BWA [4] . Duplicate reads were removed using Samtools rmdup, with 91% of the target bases with at least 10× coverage and >75% having over 30× coverage. The coverage at each targeted base and each targeted gene was calculated first by using the genome CoverageBed utility from the BEDTools software package to generate the coverage across the genome and then narrowing the resulting bedgraph to the targeted regions using a custom Galaxy workflow. The Unified Genotyper from the Genome Analysis Toolkit was used to call variants in the sequence data [5] . The resulting amino acid change, if any, from the variants was determined using SLATE, an in-house application. The variants were filtered to remove variants with a depth of coverage of <10, a positive-strand bias, and variants with <3 reads supporting the alternate allele.
Sequencing and genotyping concordance
The concordance between the Affymetrix 6.0 array genotype calls and the exome sequencing calls was determined by comparing the genotype calls overlapping the exome target region with the Unified Genotyper calls.
Determination of putative causative alleles
The causative allele is predicted to be rare; the variants were further filtered to remove all db SNPs from build 132 not tagged as being a clinical submission, all 1000 Genome SNPs from the pilot release and all other SNPs from an in-house database of exome sequences. The variants were further filtered to remove all synonymous mutations as identified by an in-house script. The variants shared by the proband and the two affected siblings were determined by intersecting the variant lists for each at sites where all three had sufficient coverage to call SNPs. The variants from this list not found in the unaffected father, sibling and wife were determined for each site where the unaffected individuals had sufficient coverage to call SNPs. Likewise, the variants where the unaffected father was heterozygous and the three affected siblings had a homozygous call were determined using a similar approach. Finally, variants unique to each sample were determined by removing all intersecting variants from the other samples.
Plasma FGF23 measurement
Intact plasma FGF23 measurements used a two-site enzyme-linked immunosorbent assay (Kainos Laboratories) in which monoclonal antibodies recognize full-length FGF23. 'C-terminal' FGF23 was measured by ELISA (Immutopics International), which employs polyclonal antibodies to the C-terminal domain of FGF23 (Table 3) .
R E S U LT S
Clinical phenotype of the proband and affected and unaffected family members The proband was referred at age 42 for hyperphosphatemia management. History was significant for below and above the knee amputations at ages 34 and 41, coronary artery calcification, tendon ossification and diverticulitis, but was negative for kidney stones or fractures. Physical examination revealed ear and digit calcified granules, cold, stiff hands with diminished finger flexion and extension, amputations and no vascular bruits. Imaging showed extensive vascular calcification involving the aorta, mesenteric, renal, carotid, limb, heart and brain vasculature along with ectopic calcification (Figure 1 ). Laboratory assessments demonstrated hyperphosphatemia despite normal renal function, normoalbuminuria, normal serum calcium, low parathyroid hormone (PTH) and a lack of significant hypervitaminosis D (Table 1) . His total cholesterol was 171 mg/dL, triglycerides 165 mg/dL, low-density lipoprotein 83 mg/dL and high-density lipoprotein 55 mg/dL.
Two siblings had similar symptoms, one with multiple digit amputations. The pedigree in Figure 2 is a summary of the proband's family history. Affected family members had characteristics similar to the proband (two sisters TC6 and TC8 in table). The maximal tubular reabsorption of phosphate per unit volume of glomerular filtration rate (GFR) (TmP/GFR) was abnormal and high only in the affected, except for the youngest subject whose TmP/GFR was high but normal for her age. Urinary calcium tended to be higher in affected than unaffected siblings although consistently in the normal range. Serum calcium, also normal, was higher in two affected siblings than in unaffected subjects. PTH tended to be suppressed in affected family members. These features, coupled to the hyperphosphatemia, are consistent with a causative mutation in FGF23 (Table 1) .
Morphology
Vessels from capillaries to medium-sized arteries were evaluated in the amputation specimen ( Figure 3 ). Most arteriolar and small artery walls had primarily circumferential or segmental internal elastic lamina (IEL) calcification with extension toward the media. The osteocyte marker osteonectin stained capillaries and arterioles most consistently, while larger arteries showed variable staining. Arterioles and arteries, regardless of medial calcification, showed osteonectin staining in the muscularis smooth muscle cells, which retained smooth muscle actin expression. There was no extracellular osteonectin staining. There Full exomic sequencing of the proband and his affected and unaffected family members A gene mutation in FGF23, Klotho or GALANT3 was suspected, but the prominent vascular calcification expanded our search to include potential novel mediators of vascular calcification and/or phenotypic modulators. Whole-exome sequencing was performed in six family members ( proband, two affected and one unaffected sibling, his unaffected father and his wife). The proband's mother had expired, but she had no history related to vascular calcification. Her genetic sequence was imputed based on available family data. Among 17 variants that showed differences between the exomes of affected and unaffected individuals, a novel Q67K recessive FGF23 mutation was detected, which was inherited from the father in all affected siblings in compound heterozygosity with a 5.25-Mb deletion from their mother on the other allele. Not previously reported, this change is within a highly conserved N-terminal domain of FGF23, making a compelling candidate for the disease-causing mutation. The variation causing the Q67K mutation was predicted to be damaged by Polyphen2 and a likelihood ratio test [6, 7] . This variant was found to be hemizygous-confirmed by Sanger sequencing-in the three affected individuals, heterozygous in the father and unaffected sibling, and it was not found in the proband's unaffected wife. The 5.25-Mb deletion was identified via LOH analysis (Figure 4) , was not present in unaffected family members and is deduced to be inherited from the mother. None of the other variants were hypothesized to be causative for TC (Table 2) .
Three-dimensional structural analysis of FGF23 Q67K variant The 3D structure of FGF23 was mutated to Q67K in a Swiss-PDB Viewer and visualized using Chimera. Supplemental Table 1 . Clinical characteristics of the proband and his affected and unaffected family members (sisters TC6 and TC8 are affected subjects) F I G U R E 2 : Pedigree of three generations of a family with several members affected by tumoral calcinosis. A family with three affected individuals (shaded black) was examined using both Affymetrix 6.0 genotyping array and whole-exome sequencing. All 13 living individuals were genotyped using the Affymetrix array and 6 individuals, denoted by an E, were exome-sequenced. The proband is denoted by an arrow. 
O R I G I N A L A R T I C L E
A n o v e l m u t a t i o n i n F G F 2 3 Figure S1 shows the wild-type FGF23 3D structure. S71, a residue previously reported to be mutated in TC patients [8] , is near the Q67 variant.
Genetic modifiers
It was posited that other variants present in the affected subjects' genome might have a modifying effect. Analysis of the genotyping array and exome sequencing data showed three potential candidate genes. Haploinsufficiency of Wnt5, a gene located in the deleted region of the maternal copy of chromosome 12 in the affected individuals, is the one variation shared across all three affected siblings. The proband and one affected sibling also shared a heterozygous missense mutation in TNFRSF11B, which encodes osteoprotegerin. The proband also had a heterozygous missense mutation in SFRP1. The encoded protein, secreted frizzled-related protein 1 (SFRP1), which is upregulated in rats fed a high-phosphorous diet [9] , has demonstrated interactions with Wnt proteins. No association between the phenotype severity and the potential modifiers identified secondary to the greatly varied medical care each of the affected received. This cluster of variation in genes involved in bone loss, and vascular calcification inhibition might have modified the typical hyperphosphatemic TC caused by the FGF23 mutation and may have led to more severe vascular calcification.
Circulating plasma FGF23 levels Affected subjects had high levels of plasma C-terminal FGF23; however, intact FGF23 was undetectable by ELISA compared with carrier individuals (Table 3) .This indicates that the 12p13 genomic deletion in combination with the FGF23 missense mutation resulted in the absence of circulating, intact FGF23.
D I S C U S S I O N
We describe a family with an FGF23 mutation whose unique clinical phenotype in affected members is severe vascular calcification requiring amputations. In this family, vascular calcification, and not TC, was the most clinically significant problem. The IEL, medial and capillary vascular calcification occurred in association with hyperphosphatemia and hypophosphaturia. Overt hypercalcemia was not present, although serum calcium levels were at the upper range of normal, and there was a tendency for higher urinary calcium excretion and suppressed PTH levels. Other risk factors for vascular calcification were absent, including hyperparathyroidism, hypervitaminosis D, hypercholesterolemia, hypertension, advanced age, diabetes, albuminuria and CKD. Using exomic sequencing, a novel recessive Q67K mutation in FGF23 inherited in compound heterozygosity with a null allele was causative. This family's phenotype is unique among other reported mutations in the FGF23-αKlotho-GALNT3 spectrum of mutations causing TC because of the vascular calcification severity. The histopathologic characterization of the calcification process and the use of full exome sequencing to explore a role for genetic modifiers is also unique. These data suggest that in these patients, hyperphosphatemia appeared to be the major contributor to TC and vascular calcification severe enough to induce ischemia requiring amputations.
Intimal vascular calcification occurs in arteries of all sizes, but particularly in large-and medium-sized vessels in atherogenesis in the general population, and in both the intima and the media in CKD and ESRD, more prominently in the media. High serum phosphorus levels have been implicated as a risk factor for vascular calcification and cardiovascular events in both groups. High serum phosphorus is associated with a higher risk of coronary artery calcification in individuals with normal renal function [10] and in these, a higher risk of death and additional cardiovascular events in patients with a prior myocardial infarction [11, 12] . In the Multi-ethnic Study of Atherosclerosis (MESA), in moderate CKD, serum phosphorus levels correlated with coronary artery and aortic calcification [13] . In ESRD, the Dialysis Outcomes and Practice Patterns Study (DOPPS) and the USRDS Wave study showed associations between serum phosphorus and calcium-phosphorus product and mortality risk [14, 15] . The evidence shows association between hyperphosphatemia, arterial stiffness, vascular calcification and left ventricular hypertrophy [16] . Thus, the distinct etiopathogenesis, localization, severity and rapidity of calcification progression in CKD and ESRD, coupled to the association between vascular calcification and mortality in this group, make understanding and preventing this process extremely important. The proband's vascular calcification involved the media in all size arteries available for review, with smaller arteries and arterioles often showing circumferential IEL calcification. Medial calcification has been associated with CKD and ESRD. However, there is controversy regarding the relationship between IEL and medial calcification, with some investigators indicating these are independent processes and others suggesting IEL calcification precedes or initiates medial calcification [17, 18] . Prominent IEL calcification has been reported in various conditions including pseudoxanthoma elasticum, Buerger's disease and Marfan syndrome, but not hyperphosphatemia alone, a novel finding in this subject [1, 19] . Arteries and arterioles with and without calcification had endothelial and smooth muscle cell osteonectin expression, indicating osteogenic conversion. In contrast with ESRD patients, the hyperphosphatemia with normal renal function in this patient was associated with preservation of a smooth muscle morphology in vascular smooth muscle cells expressing osteocytic markers [20, 21] . These findings demonstrate some unique features of the vascular calcification where hyperphosphatemia appears to be the major contributing factor.
Vascular calcification is a highly regulated process [1]. Identification of key mediators as therapeutic or preventive targets has utility, and the role of phosphorus has been a principal object of interest [22] . Due to multiple confounders in clinical renal disease, the specific role of phosphorus in vascular calcification has been approached experimentally. After subtotal nephrectomy, rats fed a high phosphorus diet developed medial vascular calcification [9, 23] , and aortic expression arrays revealed mRNAs consistent with the appearance of an osteoblast phenotype [9] . Other studies utilized targeted mutations to induce isolated hyperphosphatemia. In cultured vascular smooth muscle cells, only high phosphorus medium under F I G U R E 4 : Genotyping and exome sequencing analysis of the FGF23 region. Thirteen individuals were analyzed using the Affymetrix 6.0 array and six of those were exome-sequenced. (A) The Affymetrix genotypes on chromosome 12 from 0 to 9 Mb were viewed using dChip. Regions of homozygosity were displayed as dark gray bars. Affymetrix's Genotyping Console identified a region in the three affected individuals that showed LOH (dark box), which contained the FGF23 gene. The cluster graphs of heterozygous calls in this region in the three affected individuals were examined and found to be miscalled by the software. The size of the region in the three affected individuals is indicative of a deletion on the maternal chromosome spanning ∼5.25 Mb. Informative genotype calls from markers surrounding FGF23 were examined and individual haplotypes phased for four individuals (TC2-proband, TC5-unaffected brother, TC1-father and TC4-unaffected brother). The proband possesses one copy of the paternal allele carrying the FGF23 variant and the maternal allele with a deletion (null allele), spanning 5.25 Mb, while the two unaffected brothers carry the paternal allele carrying the variant and a maternal allele lacking the deletion. (B) The FGF23 variant found in the three affected individuals (top track) was viewed in USCS Genome Browser along with seven previously identified tumoral calcinosis causing variants in FGF23 (bottom track), with the variants labeled by their amino acid change. The variant from this study, Q67K, was found in a region containing three other known variants. the control of the sodium-dependent phosphate cotransporter, Pit-1, induced mineralization and expression of osteoblastic markers osteocalcin and Cbfa-1 [24, 25] . Pit-1 inhibition attenuated these changes [24] . In cultured endothelial cells [26] , high medium phosphorus, especially with high calcium concentrations, induced apoptosis, which has been implicated indirectly in the calcification cascade in vascular smooth muscle cells and chondrocytes [27, 28] . In mice, FGF23 ablation induced hyperphosphatemia, hypercalcemia, hypervitaminosis D, suppressed PTH levels, shortened survival, soft-tissue calcification and calcified small-and medium-sized arteries reminiscent of the proband's phenotype herein. Dietary phosphorus restriction, but not vitamin D restriction, attenuated the calcification [29] , implicating hyperphosphatemia as the cause. Recent data implicate FGF23 in the inhibition of vascular calcification in dialysis patients [30] , an observation potentially congruent with our finding of circulating inactive FGF23 fragments associated with severe vascular calcification. C-terminal fragments of FGF23 (between residues 180 and 251) have been shown to competitively inhibit full-length FGF23 interactions with FGFRs and αKlotho [31] . Whether the significantly elevated C-terminal fragments observed in our TC patients potentially inhibit FGF23 or local FGFs in the vasculature, or affect vasculature and renal FGFRs differently, is currently unclear. Five other FGF23 mutations causing TC have been described. Typical phenotypic findings included calcification around joints including hips, elbows, shoulders and knees, occasionally with diaphysitis, hyperostosis, arterial aneurysms, dental abnormalities and angioid retinal streaks [32] . Hyperphosphatemic familial TC has been associated with inappropriately high or normal vitamin D levels, and normal serum calcium [32, 33] , but these cases had inconsistent vascular calcification severity. Larsson et al. [31] and Chefetz et al. [32] described missense mutations in patients with TC who demonstrated vascular calcification on imaging; no amputations were described [32, 34, 35] . FGF23 mutations were described by Araya et al. [33] , Garringer et al. [34] and Masi et al. [36] causing TC without vascular lesions. In the family described herein, it is predicted based on the effects of the mutation that the affected subjects have circulating C-terminal FGF23 fragments incapable of receptor binding.
Varied clinical presentations despite mutations in the same gene suggest that genetic modifiers may modulate the TC phenotype. Using full exomic sequencing in this family, three potential genetic modifiers were identified that may contribute to the severity of the vascular calcification. Haploinsufficiency of Wnt5 was identified in all three affected subjects. Wnt5 haploinsufficeincy has been shown to cause bone loss [37] and associated vascular calcification in mice [38] . The expression of Wnt5a has also been shown to correlate with the severity of atherosclerosis [39] . Its role as a genetic modifier in this family remains to be determined. Two affected subjects shared a heterozygous missense mutation in TNFRSF11B, the gene-encoding osteoprotegerin. Osteoprotegerin has been implicated in vascular calcification inhibition, making it a potential gene modifier in this setting [40, 41] . Finally, the proband also had a heterozygous missense mutation in SFRP1. The regulation of SFRP1 by dietary phosphorus [9] and the known interactions between SFRP1 and Wnt signaling proteins, potentially facilitating an adaptation to inhibit calcification, also implicate this mutation as a candidate modifier of the FGF23 mutation phenotype. Thus, in the study of this family, full exomic scanning disclosed underlying genetic modifiers that may contribute to between-and within-family differences in the phenotypic expression of TC caused by the FGF23 mutation.
In conclusion, the novel FGF23 mutation in this kindred resulted in hyperphosphatemia, hypophosphaturia, arterial and capillary calcification and an ossifying cell phenotype in the absence of classical risk factors. Full genomic scanning identified potential genetic modifiers that may contribute to the phenotypic variation in vascular calcification observed. This experiment of nature supports the contention that in human, as in experimental models, hyperphosphatemia is sufficient to produce bone differentiation proteins in vascular wall cells and vascular calcification severe enough to require amputation due to ischemia.
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